Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection: Systematic Review and Meta-analysis.

Mouhand Faisal Hamad MohamedChristopher WardAzizullah BeranMohamed A AbdallahJoseph AsemotaColleen R Kelly

Published in: Journal of clinical gastroenterology (2023)

Our meta-analysis comprising real-world data revealed lower rCDI in patients receiving BEZ and supported its efficacy and safety when added to SOC therapy. The results were consistent across various subgroups. Available cost-effectiveness analyses mostly support BEZ+SOC cost-effectiveness compared with SOC alone.

Keyphrases

systematic review
clostridium difficile
electronic health record
big data
single cell
stem cells
machine learning